As of October 2025, the Australian market has shown resilience with the S&P/ASX 200 index climbing past the 9,000-point mark despite mixed economic signals such as weak jobs data and stronger-than-expected inflation. In this dynamic environment, identifying high-growth tech stocks requires careful consideration of factors like market sentiment shifts and sector-specific developments that could influence their performance.
Top 10 High Growth Tech Companies In Australia
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Pureprofile | 11.53% | 37.56% | ★★★★★☆ |
| Infomedia | 7.00% | 20.05% | ★★★★★☆ |
| Clinuvel Pharmaceuticals | 22.04% | 26.15% | ★★★★★☆ |
| Pro Medicus | 19.44% | 20.97% | ★★★★★☆ |
| Immutep | 104.12% | 46.46% | ★★★★★☆ |
| Kinatico | 13.02% | 40.53% | ★★★★☆☆ |
| BlinkLab | 104.90% | 101.40% | ★★★★★★ |
| Artrya | 49.60% | 61.45% | ★★★★★☆ |
| Wrkr | 53.03% | 122.27% | ★★★★★★ |
| FINEOS Corporation Holdings | 9.22% | 57.85% | ★★★★☆☆ |
Click here to see the full list of 21 stocks from our ASX High Growth Tech and AI Stocks screener.
Let's uncover some gems from our specialized screener.
Data#3 (ASX:DTL)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Data#3 Limited offers information technology solutions and services across Australia, with a market capitalization of approximately A$1.37 billion.
Operations: The company generates revenue through three primary segments: Services (A$271.91 million), Software Solutions (A$72.61 million), and Infrastructure Solutions (A$508.14 million).
Data#3 Limited, a contender in Australia's tech landscape, recently showcased robust financial performance with annual revenue climbing to AUD 853 million, up from AUD 806 million the previous year. This growth is complemented by an increase in net income to AUD 48.19 million. The firm's commitment to innovation is evident from its R&D focus, though specific expenditure figures are not disclosed. With a forecasted revenue growth rate of 23.2% per year, Data#3 outpaces the broader Australian market's expected growth of 5.9%. Additionally, the company declared a fully franked dividend of AUD 0.15 per share for the first half of fiscal year ending June 2025, underscoring its stable financial health and appeal to shareholders looking for consistent returns amidst rapid expansion in tech sectors like cloud computing and cybersecurity solutions.
- Click here to discover the nuances of Data#3 with our detailed analytical health report.
Explore historical data to track Data#3's performance over time in our Past section.
Pro Medicus (ASX:PME)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Pro Medicus Limited is a healthcare informatics company that develops and supplies imaging software and radiology information system software to hospitals, imaging centers, and healthcare groups across Australia, North America, and Europe, with a market cap of A$30.58 billion.
Operations: The company generates revenue primarily from producing integrated software applications for the healthcare industry, amounting to A$212.98 million.
Pro Medicus, a standout in the Australian tech scene, demonstrated substantial financial growth with its latest earnings report showcasing a 39.2% surge in annual earnings, significantly outpacing the Healthcare Services industry's average of 13%. This performance is anchored by impressive revenue figures which jumped from AUD 166.33 million to AUD 220.54 million. The company's strategic emphasis on R&D has fostered innovation and efficiency, further evidenced by their recent buyback of shares for AUD 1.5 million and an increased dividend payout to shareholders at 30 cents per share, up from last year’s 22 cents. These moves reflect not only Pro Medicus' robust financial health but also its commitment to returning value to its investors while continuing to innovate within the tech space.
- Click here and access our complete health analysis report to understand the dynamics of Pro Medicus.
Gain insights into Pro Medicus' historical performance by reviewing our past performance report.
Xero (ASX:XRO)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Xero Limited, along with its subsidiaries, offers online business solutions for small businesses and their advisors across various regions including Australia, New Zealand, the United Kingdom, North America, and other international markets, with a market capitalization of A$25.61 billion.
Operations: The company generates revenue primarily from providing online solutions for small businesses and their advisors, amounting to NZ$2.10 billion. It operates across multiple regions, offering a platform that supports business operations and financial management.
Xero, an Australian software company, is distinguishing itself in the high-growth tech sector with a robust financial trajectory. The firm's annual revenue growth stands at 14.2%, slightly below the ambitious 20% threshold yet surpassing the national market average of 5.9%. Notably, Xero's earnings have surged by 30.4% over the past year, outperforming its industry peers and are projected to continue growing at an impressive rate of approximately 24% annually. This growth is supported by substantial investments in R&D, fostering innovation that keeps Xero competitive in a dynamic market environment marked by rapid technological advances and shifting business models towards SaaS platforms. Additionally, recent strategic moves such as a follow-on equity offering raising AUD 129.52 million highlight Xero’s proactive approach in capital management and expansion strategies.
- Delve into the full analysis health report here for a deeper understanding of Xero.
Assess Xero's past performance with our detailed historical performance reports.
Key Takeaways
- Delve into our full catalog of 21 ASX High Growth Tech and AI Stocks here.
- Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
- Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.
Curious About Other Options?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Pro Medicus might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com